VivoSeq
Other

Gastrointestinal Disease

26

Pipeline Programs↗

1

Active Trials↗

15

Companies Involved↗

Gastrointestinal Disease is an emerging landscape with 26 programs across 15 companies. The most active players are Novo Nordisk, Exela Pharma Sciences, LLC., Johnson & Johnson. 16 therapies are approved with 1 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

50/100

Pipeline Velocity

0/100

Mech. Concentration

11/100

Completion Rate

75/100

Attrition Rate

13/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Novo Nordisk logo

Novo Nordisk

1 program

Phase 1E

Exela Pharma Sciences, LLC.

1 program

Phase 1Johnson & Johnson logo

Johnson & Johnson

2 programs

Phase 2AbbVie logo

AbbVie

1 program

ApprovedAstraZeneca logo

AstraZeneca

1 program

ApprovedTeva logo

Teva

1 program

Approved

Pipeline

Programs by Phase

Analysis

Modality Breakdown

97%

Small molecule

28 of 29 classified programs — the dominant modality here.

3%ALL OTHERSPeptide13%

Small molecule leads; the ring shows all 29 classified programs, each share of the total. Modality classified for 100% of 30 pipeline programs.

Analysis

Trial Status

8

clinical trials

Completed3 · 38%
Unknown status3 · 38%
Withdrawn1 · 13%
Active, not recruiting1 · 13%

Clinical Trials

Trial Activity

8 trials

Ritual Synbiotic+, a Dietary Supplement
Active, not recruiting·CColorado State University·Preclinical·NCT06834984·60 enrolled
Investigation of the Effect of Upper Gastrointestinal Disease on the Pharmacokinetics of Oral Semaglutide in Subjects With Type 2 Diabetes.
Completed·Novo Nordisk logoNovo Nordisk·Phase 1·NCT02877355·55 enrolled
A Randomized Comparative Pharmacokinetic Study of Oral Ganciclovir After Treatment With Intravenous Ganciclovir for Cytomegalovirus Gastrointestinal Disease in AIDS Patients
Completed·National Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00000768·24 enrolled
A Pharmacy-based Study to Learn More About How Well Iberogast Works, How it Affects the Body, How it is Used, and User Satisfaction in Patients With Functional and Motility-related (Stomach and Bowel Movement-related) Gastrointestinal Diseases, Including Irritable Bowel Syndrome
Completed·Bayer logoBayer·N/A·NCT04993989·843 enrolled
Collaborative Cognitive Behavioral Therapy / Hypnotherapy for Treatment of Pediatric Functional Gastrointestinal Disease
Withdrawn·SSeton Healthcare Family·N/A·NCT01966341
Colonoscopic Probiotics Infusion for Functional Gastrointestinal Disease
Unknown status·FFirst Affiliated Hospital Xi'an Jiaotong University·Phase 4·NCT05366335·160 enrolled
Endoscopic Vital Nerve Staining in Gastrointestinal Diseases
Unknown status·—·Phase 1·NCT05232357·100 enrolled
Study on the Rule and Mechanism of Treating Functional Gastrointestinal Diseases From the Perspective of Liver and Spleen
Unknown status·XXiyuan Hospital of China Academy of Chinese Medical Sciences·Phase 4·NCT04454996·100 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)